Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer

NCT03572478 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

12

Enrollment

OTHER

Sponsor class

Stopped The study was terminated due to lack of efficacy.

Conditions

Prostate Cancer
Endometrial Cancer

Interventions

DRUG: Rucaparib
DRUG: Nivolumab

Sponsor

University of Chicago

Collaborators

[object Object]
[object Object]